We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: cardiovascular outcomes
MedXY News
EnglishTag

cardiovascular outcomes

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD
Diabetes & Endocrinologycardiovascular outcomesMASLD

SGLT2 Inhibitors Emerge as Superior Choice for Cardiovascular Protection in Patients with T2DM and MASLD

By MedXY|Jan 7, 2026

A nationwide target trial emulation reveals that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and mortality compared to other oral antidiabetics in patients with concurrent T2DM and MASLD, with benefits partiall

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models
Cardiologycardiovascular outcomesGLP-1 receptor agonists

Semaglutide Extends Survival in Non-Overweight Type 2 Diabetes Patients: New Evidence Challenges BMI-Centric Treatment Models

By MedXY|Jan 4, 2026

A large-scale retrospective study demonstrates that semaglutide reduces all-cause mortality by 46% in non-overweight patients with Type 2 diabetes compared to DPP-4 inhibitors, highlighting cardioprotective benefits independent of weight re

AI-Based OCT Analysis Outperforms Human Experts in Predicting Outcomes from Non-Culprit Lesions: Insights from the PECTUS-AI Study
AIartificial intelligencecardiovascular outcomes

AI-Based OCT Analysis Outperforms Human Experts in Predicting Outcomes from Non-Culprit Lesions: Insights from the PECTUS-AI Study

By MedXY|Jan 3, 2026

The PECTUS-AI study demonstrates that AI-based identification of thin-cap fibroatheromas using OCT provides superior prognostic value for cardiovascular events compared to manual analysis, particularly when assessing the entire imaged coron

Endoscopic Radial Artery Harvesting Superior to Open Technique for Hand Function and Neurologic Protection in CABG
CardiologyCABGcardiovascular outcomes

Endoscopic Radial Artery Harvesting Superior to Open Technique for Hand Function and Neurologic Protection in CABG

By MedXY|Dec 31, 2025

A randomized trial reveals that endoscopic radial artery harvesting for CABG leads to better patient-reported hand function and significantly fewer neurologic deficits compared to the traditional open technique, potentially redefining the s

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial
Cardiologycardiovascular outcomeschronic kidney disease

Comparative Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Chronic Kidney Disease and Cardiovascular Disease: Integrated Insights from the DANFLU-2 Trial

By MedXY|Dec 25, 2025

The DANFLU-2 trial demonstrates that high-dose influenza vaccine provides superior protection against influenza-related hospitalizations in chronic kidney disease and reduces cardiorespiratory hospitalizations in older adults irrespective o

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
Cardiologyatrial fibrillationcardiovascular outcomes

Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY|Dec 22, 2025

This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy
Cardiologycardiovascular outcomestirzepatide

Tirzepatide Achieves Cardiovascular Noninferiority Against Dulaglutide: A Milestone in Dual Incretin Therapy

By MedXY|Dec 18, 2025

The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile

Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed
Cardiologycardiovascular outcomesmineralocorticoid receptor antagonists

Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed

By MedXY|Nov 30, 2025

A 2025 systematic review and meta-analysis found that patients with primary aldosteronism whose renin rose after mineralocorticoid receptor antagonist therapy had substantially lower cardiovascular event rates and possibly lower mortality,

SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations
Cardiologycardiovascular outcomesCKM

SGLT2 Inhibitors Remain Protective Even After Severe eGFR Decline: Pooled Trial Analysis Across Cardio‑Renal‑Metabolic Populations

By MedXY|Nov 28, 2025

A pooled analysis of five randomized trials (n=26,946) found that severe eGFR deterioration (<25 and <20 ml/min/1.73 m2) increased cardiovascular risk nearly twofold, but SGLT2 inhibitors reduced that risk and retained benefit regardl

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit
Cardiologycardiovascular outcomesobesity

Semaglutide’s Cardioprotection in SELECT: Beyond Weight Loss — Waist Reduction Explains a Third of the Benefit

By MedXY|Nov 11, 2025

In the SELECT trial, weekly semaglutide 2.4 mg reduced major adverse cardiovascular events in people with overweight/obesity without diabetes. Benefits were largely independent of baseline adiposity and weight loss; waist circumference redu

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial
Cardiologycardiovascular outcomesEvolocumab

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial

By MedXY|Nov 9, 2025

In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study
Cardiologycardiovascular outcomesGLP-1RA

GLP‑1 Receptor Agonists Provide Greatest MACE Reduction in Type 2 Diabetes — Evidence from a Large US Comparative-Effectiveness Study

By MedXY|Nov 7, 2025

In a 241,981-patient emulated trial using modern causal methods, sustained GLP‑1RA use yielded the lowest 2.5‑year MACE risk, followed by SGLT2is, sulfonylureas, and DPP4is; the GLP‑1RA advantage over SGLT2is was greatest in older adults an

Low-Dose Colchicine in Acute Myocardial Infarction: Insights from an Updated Meta-Analysis
Cardiologyacute myocardial infarctioncardiovascular outcomes

Low-Dose Colchicine in Acute Myocardial Infarction: Insights from an Updated Meta-Analysis

By MedXY|Oct 12, 2025

An updated meta-analysis evaluates the effects of 0.5 mg colchicine on clinical outcomes after acute myocardial infarction, showing reduced hospital readmission but increased diarrhea risk without significant impact on major cardiovascular

Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes
Cardiologycardiovascular outcomesHypertension

Balancing Risks and Benefits: Individual Data Analysis of Intensive vs. Standard Blood Pressure Control on Cardiovascular and Renal Outcomes

By MedXY|Oct 11, 2025

A large pooled analysis shows that intensive blood pressure control reduces cardiovascular events with a modest increase in adverse effects, resulting in an overall net clinical benefit.

β-Blockers in Post-Myocardial Infarction Patients with Mildly Reduced Ejection Fraction: A Meta-Analysis of Randomized Trials
Cardiologycardiovascular outcomesmyocardial infarction

β-Blockers in Post-Myocardial Infarction Patients with Mildly Reduced Ejection Fraction: A Meta-Analysis of Randomized Trials

By MedXY|Oct 11, 2025

This meta-analysis reveals that β-blocker therapy reduces mortality and adverse cardiovascular events in myocardial infarction patients with mildly reduced left ventricular ejection fraction (40–49%), extending benefits beyond reduced LVEF

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials
Cardiologycardiovascular outcomesheart failure

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

By MedXY|Oct 10, 2025

Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial
Cardiologycardiovascular outcomesheart failure

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

By MedXY|Oct 10, 2025

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept

Cardiologycardiovascular outcomeschronic kidney disease

Exploring the Impact of Reduced Left Ventricular Function on Outcomes After PCI in Chronic Kidney Disease Patients

By MedXY|Oct 9, 2025

Reduced left ventricular ejection fraction (LVEF) adversely affects survival and myocardial infarction risk in patients with chronic kidney disease undergoing percutaneous coronary intervention, despite no significant difference in overall

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence
Cardiologycardiovascular outcomesinfluenza vaccine

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial and Related Evidence

By MedXY|Oct 9, 2025

This review synthesizes evidence on high-dose versus standard-dose influenza vaccines for cardiovascular outcomes in older adults, focusing on the large DANFLU-2 trial and complementary studies, highlighting modest cardiovascular benefits a

DIALIZE-Outcomes Trial: Sodium Zirconium Cyclosilicate Effect on Cardiovascular Outcomes in Hemodialysis Patients with Hyperkalemia
Cardiologycardiovascular outcomesHemodialysis

DIALIZE-Outcomes Trial: Sodium Zirconium Cyclosilicate Effect on Cardiovascular Outcomes in Hemodialysis Patients with Hyperkalemia

By MedXY|Oct 9, 2025

The DIALIZE-Outcomes trial assessed sodium zirconium cyclosilicate (SZC) in controlling predialysis hyperkalemia among hemodialysis patients but found no reduction in arrhythmia-related cardiovascular events despite improved potassium contr

Prev
2 / 3
123
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities